Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to EDIT. [ FAQ on what and how to ask] For non-EDIT questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 11 Hurley Street, Cambridge, MA, United States, 02141
Employees: 87
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
President, CEO & Director
Senior VP & CFO
Executive VP & Chief Scientific Officer
Co-Founder & Scientific Advisory Board Member
Co-Founder & Scientific Advisory Board Member
Executive VP and Chief Technical & Quality Officer
Senior VP, General Counsel & Corporate Secretary
Vice President of People
Senior VP & Chief Business Officer
Senior Vice President of Development and Program Leadership
My Watchlist
